Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Dongre
Ashok R. Dongre, Newton, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20080286764 | Method of mass spectrometry - A method of identifying molecules of biological origin is disclosed. The molecules are identified and the basis of the accurately determined mass to charge ratio of the molecules and at least a further physico-chemical property such as elution time or charge state. Further physico-chemical properties may be used. The experimentally determined accurate mass and physico-chemical properties can then be compared with a look-up table of information. The look-up table may generated or physico-chemical properties of data in a conventional database may be calculated. The ability to recognise and preferably identify the same molecules in two different samples may be used to determine whether a particular biological molecules has been expressed differently in an experimental sample relative to a control sample. | 11-20-2008 |
Ashok Ramesh Dongre, Newtown, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20100184125 | BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO INSULIN GROWTH FACTOR-1 RECEPTOR MODULATORS - IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer. | 07-22-2010 |
| 20100233172 | METHODS OF INHIBITING QUIESCENT TUMOR PROLIFERATION - Improved compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders, and methods of screening to identify compounds for such treatments. | 09-16-2010 |
Kedar Dongre, Hillsboro, OR US
| Patent application number | Description | Published |
|---|---|---|
| 20090171606 | SEMICONDUCTOR MANUFACTURE PERFORMANCE ANALYSIS - A software architecture, design and implementation that enables efficient transistor performance analysis across multiple levels of parameter granularity with interactive drill-down, drill-across capability, for use during semiconductor technology development. The software may include several features, such as highly modular, robust architecture to enable analysis across the multiple granularity of transistor performance data, i.e., per die, material group, and aggregate, GUI-based template configuration to specify the analysis across the multiple levels in a uniform set of operations, subsystems to execute the template specified with the GUI, integration of pass-fail analysis analytics, interactive drill-down on particular data points of user interest in automatically generated charts, and drill-across capability allowing linking of data points highlighted on a single chart to those that are correlated in all other charts. Other embodiments are described. | 07-02-2009 |
| 20090241075 | TEST CHIP VALIDATION AND DEVELOPMENT SYSTEM - Embodiments of an IC design system for test row/structure layout design are described in this application. The design system may include a test chip complier database, a test chip complier engine (TCCE), and a user interface module. The TCCE may be configured to communicate with at least the test chip compiler database and the user interface module, and configured to allow a user to automatically generate a test chip layout by providing an integrated circuit design system. With the system, a user can automatically generate a design by specifying the test row or test structure layout requirements for the design using sets of predefined templates, changing design template parameters using a table driven input format, scheduling generation of the design on a preferred layout design tool, visually inspecting the generated design for errors, and/or applying version controls to the generated design. Other embodiments are described. | 09-24-2009 |
M. Keerthidhara Dongre, Bangalore IN
| Patent application number | Description | Published |
|---|---|---|
| 20100161714 | RELIABLE PROCESSING OF HTTP REQUESTS - A monitoring tool provided according to an aspect of the present invention causes an HTTP request to be resubmitted to another server system if a server system, to which the same HTTP request has been earlier submitted, is detected to have failed without completing processing of the request. In one embodiment, the server system is deemed to have failed upon absence of completion of requests for a pre-specified duration. As an alternative or in addition, the operational status of the server system is checked periodically and the server system is deemed to have failed if it is non-operational. | 06-24-2010 |
Prashant Dongre, Mumbai IN
| Patent application number | Description | Published |
|---|---|---|
| 20100068284 | Stable Fixed Dose Topical Formulation - The present invention relates to stable fixed dose topical formulations comprising an antiacne agent and an antibiotic, which exhibit storage stability at a temperature of about 40° C. and relative humidity of about 75% for a period of at least 3 months. Particularly, the present invention relates to stable fixed dose topical formulations comprising therapeutically effective amounts of (a) adapalene-containing microspheres and (b) clindamycin, a process for their preparation thereof and their use for the treatment of acne. | 03-18-2010 |
| 20100323998 | TOPICAL COMPOSITION CONTAINING THE COMBINATION OF MUPIROCIN AND BECLOMETHASONE - The present invention relates to a topical pharmaceutical composition comprising mupirocin and beclomethasone, a process for its preparation, its use in the treatment of infected dermatoses caused by bacteria susceptible to mupirocin and in the treatment of secondary bacterial infections in patients of steroid responsive dermatoses. | 12-23-2010 |